- Home
- » Tags
- » Istradefylline
Top View
- Caffeine Acts Through Neuronal Adenosine A2A Receptors to Prevent Mood and Memory Dysfunction Triggered by Chronic Stress
- Use of Active and Inactive Stabilised Versions of the a 2A Receptor to Predict Compound Efficacy in Vitro
- Title Page Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy
- Adenosine A2A Receptors in Parkinson's Disease Treatment
- Title Page Pharmacology and Structure of Isolated Conformations
- Effects of Rifampin on the Pharmacokinetics of a Single Dose
- Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists
- Istradefylline (Nourianz™) New Drug Update
- Istradefylline (Nourianz™) EOCCO POLICY
- Novel Pharmacological Targets for the Treatment of Parkinson's Disease
- Dyskinesia in Parkinson's Disease Therapy
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- OTHER REVIEW(S) FOOD and DRUG ADMINISTRATION Center for Drug Evaluation and Research Office of Prescription Drug Promotion ****Pre-Decisional Agency Information****
- Pharmaabkommen A1 E
- Adenosine A2A Receptor Inhibition Reduces Synaptic and Cognitive
- Medical Necessity Criteria for Pharmacy Edits, 5.01.605
- NOURIANZ (Istradefylline) RATIONALE for INCLUSION IN
- CHMP Agenda of the 28-30 April 2020 Meeting
- Effect of Caffeine on Long-Term Potentiation-Like Effects Induced by Quadripulse Transcranial Magnetic Stimulation
- A View Into Upcoming Specialty & Traditional Drugs
- 2005 New Orleans, LA
- CHMP Agenda of the 25-29 January 2021 Meeting
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Istradefylline to Treat Patients with Parkinson's Disease Experiencing
- Synthesis of 8-Substituted Xanthine Derivatives and Related Pyrimido- and Diazepinopurinediones
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Istradefylline (Nourianz) Reference Number: CP.PMN.217 Effective Date: 03.01.20 Last Review Date: 02.20 Line of Business: Commercial, HIM, Medicaid Revision Log
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Effectiveness of Spinal Cord Stimulation for Painful Camptocormia with Pisa Syndrome in Parkinson's Disease: a Case Report
- The Role and Development of the Antagonist of Adenosine A2A in Parkinson’S Disease Widya Dwi Aryati, Nabilah Nurtika Salamah, Rezi Riadhi Syahdi and Arry Yanuar
- Effects of Caffeine in Parkinson's Disease: from Neuroprotection To
- Adenosine A2A Receptor Antagonists Affects NMDA
- Therapeutic Drug Monitoring of Serum Theophylline Offers a Potential Diagnostic Biomarker of Parkinson’S Disease
- Adenosine A2A Receptor Antagonist Treatment of Parkinson's Disease
- Serum Caffeine and Metabolites Are Reliable Biomarkers of Early Parkinson Disease Motoki Fujimaki, Shinji Saiki, Yuanzhe Li, Et Al
- Istradefylline 04/20
- Veyres N, Hamadjida A, Huot P. Predictive Value of Parkinsonian Primates in Pharmacological Studies, a Comparison Between the Macaque, Marmoset and Squirrel Monkey